Ionis Crushes Estimates On Partner Revenue, But A Halved TRYNGOLZA Outlook And Delayed Breakeven Reset The Story

Ionis Pharmaceuticals posted a third-quarter loss of $0.66 per share, far better than the -$1.00 consensus and the -$1.11 Earnings Whisper number, a 40.5% earnings surprise. Revenue of $243.0 million beat the $178.93 million consensus by 35.8% and grew 54.8% year over year. On the scoreboard, this was a decisive beat. The more important development was the cut to 2026 TRYNGOLZA guidance, from $100-110 million to roughly $50 million. The drug is Ionis's first launch in a large indication and the core of its long-term growth case. That is the central tension: the quarter beat estimates, while the thesis investors care most about weakened.

The quality of the beat deserves scrutiny. Research and development revenue jumped to $107 million from $41 million a year earlier, driven by $103 million of collaborative agreement revenue. Those milestone-type payments are lumpy and do not reflect durable commercial traction. Commercial revenue rose a steadier 18% to $136 million, and management noted it exceeded R&D revenue for the first time. Total revenue still slipped sequentially from $268 million in the second quarter.

The year-over-year earnings comparison depends on the basis used. Earnings Whispers' normalized figures show earnings down 10.0% year over year. The GAAP net loss, however, narrowed to $110 million from $129 million, and the non-GAAP operating loss improved to $87 million from $129 million. Meanwhile, SG&A climbed to $154 million from $97 million as Ionis funds three independent launches.

Beneath the headline, the commercial story split sharply. DAWNZERA is working. Sales grew from $16 million in the first quarter to $26 million in the second and $37 million in the third, and its $110-120 million full-year guidance was reaffirmed. TRYNGOLZA, by contrast, generated only $9 million in its first full quarter of the severe hypertriglyceridemia (sHTG) launch. Year-to-date sales of $41 million against the new ~$50 million target imply a roughly flat fourth quarter.

The call explained the friction:

• Most prescriptions still require medical exceptions.
• Commercial payer coverage has reached only 33% of lives at label.
• An expanded free-drug Quick Start program is weighing on paid conversion.
• Only about 24% of roughly 1,500 prescribers have written repeat scripts.

Management's tone shifted noticeably. In the first quarter it said momentum "continues to accelerate." In the second it described an "encouraging start" and a launch "meeting expectations." Now it uses defensive "market-building" language. Management kept the >$3 billion peak-sales ambition for TRYNGOLZA intact, but investors are being asked to trust a long-dated target while near-term evidence moves the other way.

The partnered pipeline delivered both sides of the ledger. On the positive side:

• HIBSAGO won U.S. and Japan approval, triggering a $30 million fourth-quarter milestone and future royalties.
• Sefaxersen produced a 43.1% proteinuria reduction in IgA nephropathy.
• Ulefnersen hit its Phase 3 endpoint in FUS-ALS.
• ZANVASTRO launched as Ionis's first independent neurology product.
• TRYNGOLZA received a positive CHMP opinion in sHTG.

On the negative side, pelacarsen's Lp(a) HORIZON trial failed, and eplontersen missed its primary endpoint in ATTR-CM. Those two outcomes removed meaningful future milestone and royalty potential. Combined with the slower TRYNGOLZA ramp, they pushed management's cash-flow breakeven target from 2028 to 2029. Cash fell to $1.9 billion from $2.1 billion last quarter, and the CFO acknowledged potential future financing needs. Bears have legitimate ammunition on dilution.

In fairness, total revenue, non-GAAP operating loss and the >$1.6 billion year-end cash guidance were all reaffirmed. The DAWNZERA trajectory and partner approvals keep the near-term numbers intact.

The market had largely priced in the disappointment before the report. Shares closed at $39.42 in the snapshot taken just before the release. That was down 28.4% from the $55.09 open after the July report, about 40% below the 200-day moving average of $65.90, and 38.6% below the August 25 inter-earnings high of $64.19. The stock set a 52-week low of $38.31 on November 5 and entered the print only 2.9% above it. Investor sentiment slipped from slightly positive (0.049) to slightly negative (-0.032). The change is modest in magnitude, but it shows that confidence had already cracked. Earnings Whispers' price and AVWAP trend readings are both negative, consistent with sustained selling pressure.

The bottom line is that Ionis delivered a headline beat built largely on partner payments while its own flagship launch stumbled. Halved TRYNGOLZA guidance, a one-year delay to breakeven, two major Phase 3 failures and an opened door to financing outweigh the upside surprise. DAWNZERA and a crowded approval calendar keep a credible growth story alive. Still, with shares near their lows, the stock is unlikely to recover durably until TRYNGOLZA shows paid-script momentum, broader coverage and better repeat prescribing.

Read our earnings preview for Ionis Pharmaceuticals, Inc.: https://www.earningswhispers.com/article/IONS/22781

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.